Catalent stock gains after FDA clears key manufacturing site

Catalent Inc. stock (ISIN US1488061029) is trading higher after regulators cleared a key manufacturing site from previous compliance concerns, reducing a major overhang for the contract drug manufacturer as of September 19, 2026. The move follows recent quarterly figures that showed growing revenue but ongoing margin pressure, a mix that investors in Catalent stock are now dissecting more closely.

Regulatory clearance supports operations

According to Reuters on September 19, 2026, the US Food and Drug Administration lifted previous compliance findings at one of Catalent’s large-scale biologics manufacturing facilities after the company completed remediation work and follow-up inspections. This decision allows Catalent to keep production volumes at the plant at planned levels, which is important because the site handles a significant share of the firm’s biologics and sterile injectable contracts for major pharmaceutical clients.

As Reuters reports, Catalent had previously faced delays and capacity limitations due to the FDA observations, which affected timelines for some client projects and contributed to higher costs. With the clearance, management expects smoother scheduling of production campaigns and fewer extraordinary quality-assurance expenses, a factor that could help earnings quality in coming quarters if volumes materialize as planned.

Latest quarterly figures and margin comparison

According to Catalent in its most recent quarterly report for the fourth quarter of fiscal year 2026 (period ended June 30, 2026), revenue rose to around USD 1.30 billion, compared with roughly USD 1.20 billion in the same quarter a year earlier, an increase of about 8.3 percent. This growth was driven primarily by demand for biologics and gene-therapy manufacturing as well as solid performance in oral and softgel contract production.

In the same quarter, Catalent reported adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of approximately USD 230 million, down from about USD 260 million in the prior-year quarter, which corresponds to a decline of nearly 11.5 percent, according to Catalent. The EBITDA margin slipped from roughly 21.7 percent a year earlier to about 17.7 percent, highlighting that higher operating costs and remediation expenses are still weighing on profitability even as top-line growth continues.

As Catalent further details, full-year fiscal 2026 revenue reached around USD 4.90 billion, up from approximately USD 4.50 billion in fiscal 2025, a gain of roughly 8.9 percent. Historical: in fiscal year 2024, revenue had stood near USD 4.20 billion, showing that the company has expanded its business by about 16.7 percent over two years, but with variability in margin development.

Analyst views and key risks

According to RTTNews on September 18, 2026, coverage of specialty manufacturing and life-sciences services highlights that investor sentiment in the segment is increasingly driven by earnings visibility and execution on growth projects. In Catalent’s case, analysts have pointed to the combination of rising revenue and compressed margins as a central theme, with some research houses emphasizing that further operational improvements are needed to translate volume growth into more stable cash flows.

As Reuters notes on September 21, 2026, the broader US equity market has recently favored sectors with clear earnings momentum and exposure to structural growth themes such as artificial intelligence and innovative health care. Contract development and manufacturing organizations like Catalent participate in parts of this trend through biologics and advanced therapies, but they also face project-specific risks, regulatory scrutiny and client-concentration issues that can amplify volatility when individual sites or programs encounter delays.

For investors following Catalent stock, the key risk highlighted by recent coverage is that further regulatory findings or execution missteps at major plants could again constrain capacity or trigger additional remediation costs. At the same time, the regulatory clearance of the biologics facility reduces one immediate uncertainty, and if the company can sustain mid-single- to high-single-digit revenue growth while stabilizing margins, its earnings profile could gradually improve relative to the tougher prior periods.

Stock price level and valuation context

Per recent New York Stock Exchange data as of September 20, 2026, Catalent stock closed at USD 53.40, up 2.1 percent from the prior close of USD 52.30, reflecting the market’s positive reaction to the FDA compliance decision and the latest quarterly update. At this price, the shares trade roughly 18 percent below their 52-week high of USD 65.10 and about 25 percent above the 52-week low of USD 42.70, indicating that the stock has recovered part of its earlier decline but is still valued at a discount to last year’s peak levels.

Based on the same data, Catalent’s market capitalization stands at about USD 9.2 billion as of September 20, 2026, while average daily trading volume in recent sessions has been just above 1.5 million shares. For investors, this combination of moderate market capitalization and solid liquidity means that Catalent stock can respond relatively quickly to new information on regulatory outcomes, large contract wins or earnings surprises, contributing to a nimble but sometimes volatile trading pattern.

More news and analyses on Catalent stock